Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.

IF 1.7 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2023-07-01 DOI:10.21873/anticanres.16469

Sheng-Kai Chen, Wei Lee, Yu-Ching Li, Fei-Ting Hsu, Wei-Ting Chen

{"title":"Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.","authors":"Sheng-Kai Chen, Wei Lee, Yu-Ching Li, Fei-Ting Hsu, Wei-Ting Chen","doi":"10.21873/anticanres.16469","DOIUrl":null,"url":null,"abstract":"Background/aim: Triple-negative breast cancer (TNBC) is an aggressive and deadly subtype of breast cancer, and there is an urgent need for new therapeutic strategies. The highly metastatic and anti-apoptotic characteristics are known to be the major factors causing uncontrolled growth in TNBC. Imipramine is a tricyclic antidepressant that possesses anti-inflammatory activity and has been reported to inhibit the progression of highly metastatic non-small cell lung cancer.Materials and methods: This study used MTT assay, apoptosis markers flow cytometry analysis, open-source data analysis, NF-B reporter gene assay, and western blotting to elucidate the effect of imipramine on MDA-MB-231 and 4T1 cells.Results: Imipramine induced caspase-mediated extrinsic and intrinsic apoptosis and was potentially associated with patient overall survival. Furthermore, imipramine suppressed the invasion and migration abilities and the expression of metastasis-associated proteins in TNBC cells.Conclusion: Imipramine effectively suppressed TNBC progression by inducing apoptosis and inhibiting metastasis.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"43 7","pages":"2985-2994"},"PeriodicalIF":1.7000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.16469","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background/aim: Triple-negative breast cancer (TNBC) is an aggressive and deadly subtype of breast cancer, and there is an urgent need for new therapeutic strategies. The highly metastatic and anti-apoptotic characteristics are known to be the major factors causing uncontrolled growth in TNBC. Imipramine is a tricyclic antidepressant that possesses anti-inflammatory activity and has been reported to inhibit the progression of highly metastatic non-small cell lung cancer.

Materials and methods: This study used MTT assay, apoptosis markers flow cytometry analysis, open-source data analysis, NF-B reporter gene assay, and western blotting to elucidate the effect of imipramine on MDA-MB-231 and 4T1 cells.

Results: Imipramine induced caspase-mediated extrinsic and intrinsic apoptosis and was potentially associated with patient overall survival. Furthermore, imipramine suppressed the invasion and migration abilities and the expression of metastasis-associated proteins in TNBC cells.

Conclusion: Imipramine effectively suppressed TNBC progression by inducing apoptosis and inhibiting metastasis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

丙咪嗪诱导三阴性乳腺癌细胞凋亡并抑制其转移潜能

背景/目的:三阴性乳腺癌(TNBC)是一种侵袭性和致死性的乳腺癌亚型，迫切需要新的治疗策略。高转移性和抗凋亡特性是导致TNBC不受控制生长的主要因素。丙咪嗪是一种具有抗炎活性的三环抗抑郁药，据报道可抑制高度转移性非小细胞肺癌的进展。材料和方法:本研究采用MTT法、凋亡标志物流式细胞术分析、开源数据分析、NF-B报告基因检测、western blotting等方法，探讨丙咪嗪对MDA-MB-231和4T1细胞的影响。结果:丙咪嗪诱导caspase介导的外源性和内源性细胞凋亡，并可能与患者总生存率相关。此外，丙咪嗪抑制TNBC细胞的侵袭和迁移能力以及转移相关蛋白的表达。结论:丙咪嗪通过诱导细胞凋亡和抑制肿瘤转移，有效抑制TNBC的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.